Compound meglumine diatrizoate injection and use method thereof

Abstract

The invention relates to a compound meglumine diatrizoate injection and a use method thereof. The compound meglumine diatrizoate injection is prepared from 1 part of sodium diatrizoate, 6.6 parts of meglumine diatrizoate and the balance of sterile water, wherein the total amount of the sodium diatrizoate and the meglumine diatrizoate is 90.0-110.0 percent of a labelled amount; preferably, the compound meglumine diatrizoate injection is a colorless to faint yellow clear liquid; 60 percent injection contains 292mg / ml of iodine; 76 percent injection contains 370mg / ml of iodine; the compound meglumine diatrizoate injection further comprises sodium hydroxide for adjusting the pH value to 6.5-8.0. According to the compound megumine diatrizoate injection and the use method thereof, the compound injection is stable in property, is easy to store, can be stored in a shading way at the normal temperature, is easy and convenient to operate, and can be widely applied to various people, except people suffering from iodine allergy, hepatic and renal dysfunction, active tuberculosis, multiple myeloma and hyperthyroidism.

Description

technical field [0001] The invention relates to the field of hospital reagents, in particular to clinical reagents, in particular to a compound diatrizoate meglumine injection and a use method thereof. Background technique [0002] Diatrizoate meglumine injection, indication-based contrast agent is used for intravenous and retrograde urography; angiography of brain, chest, abdomen and limbs, venography and CT; it can also be used for arthrography, fistula radiography, hysterosalpingography Angiography, endoscopic retrograde cholangiopancreatography (ERCP), sialography and other examinations. Meglumine Diatrizoate Injection is not suitable for selective coronary angiography; it cannot be used for myelography, ventriculography or cisternal angiography because it may induce symptoms of neurotoxicity; There are great disadvantages, and then PET / CT examination cannot be performed, resulting in inaccurate or delayed diagnosis of the disease, which brings great inconvenience to pa...

AI Technical Summary

Problems solved by technology

Meglumine Diatrizoate Injection is not suitable for selective coronary angiography; it cannot be used for myelography, ventriculography or cisternal angiography because it may induce symptoms of neurotoxicity; There are great disadvantages, and PET / CT examination cannot be performed, resulting in inaccurate or delayed diagnosis of the disease, which brings great inconvenience to patients and doctors.